These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 9708225

  • 21. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T, McGuigan L, Barbagallo S, Bryant C.
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [Abstract] [Full Text] [Related]

  • 22. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [Abstract] [Full Text] [Related]

  • 23. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA.
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [Abstract] [Full Text] [Related]

  • 24. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy.
    Skingle SJ, Moore DJ, Crisp AJ.
    Int J Clin Pract; 1997 Sep; 51(6):364-7. PubMed ID: 9489064
    [Abstract] [Full Text] [Related]

  • 25. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M.
    J Orthop Sci; 2003 Sep; 8(4):532-7. PubMed ID: 12898306
    [Abstract] [Full Text] [Related]

  • 26. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.
    Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI.
    Scand J Rheumatol; 1999 Sep; 28(3):152-6. PubMed ID: 10380836
    [Abstract] [Full Text] [Related]

  • 27. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.
    J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
    [Abstract] [Full Text] [Related]

  • 28. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
    Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):245-50. PubMed ID: 7923830
    [Abstract] [Full Text] [Related]

  • 29. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.
    Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA.
    J Hepatol; 1997 Feb; 26(2):325-30. PubMed ID: 9059953
    [Abstract] [Full Text] [Related]

  • 30. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH, Francis RM, Bishop JC, Rawlings DJ.
    Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
    [Abstract] [Full Text] [Related]

  • 31. Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.
    Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, Yamamoto K, Sugioka Y, Inoue A, Takaoka K, Yamamoto I, Hoshino Y, Kawaguchi H.
    J Bone Miner Metab; 2007 Sep; 25(2):130-7. PubMed ID: 17323183
    [Abstract] [Full Text] [Related]

  • 32. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.
    J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
    [Abstract] [Full Text] [Related]

  • 33. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM, Adami S, Devogelaer JP, Chines AA.
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [Abstract] [Full Text] [Related]

  • 34. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ.
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [Abstract] [Full Text] [Related]

  • 35. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD.
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [Abstract] [Full Text] [Related]

  • 36. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]

  • 37. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A.
    J Rheumatol; 1994 Oct 15; 21(10):1922-6. PubMed ID: 7837160
    [Abstract] [Full Text] [Related]

  • 38. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.
    Arch Dermatol; 2012 Mar 15; 148(3):307-14. PubMed ID: 22105813
    [Abstract] [Full Text] [Related]

  • 39. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Sawka AM, Ioannidis G, Papaioannou A, Thabane L, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Kouroukis T, Adachi JD.
    J Obstet Gynaecol Can; 2005 Aug 15; 27(8):759-64. PubMed ID: 16287007
    [Abstract] [Full Text] [Related]

  • 40. Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.
    Brown JP, Olszynski WP, Hodsman A, Bensen WG, Tenenhouse A, Anastassiades TP, Ste-Marie LG, Kendler DL, Hanley DA, Josse R, Hanly JG, Lentle B, Jovaisas A, Ioannidis G, Stephenson GF, Barton I, Pack S, Chines A, Dias R, Adachi JD.
    J Clin Densitom; 2001 Aug 15; 4(4):363-71. PubMed ID: 11748341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.